Search

for
Search:

Sort by

Research

990-1000 / 1000+ results

Proxalutamide Improves Inflammatory, Immunologic, and Thrombogenic Markers in Mild-to-Moderate COVID-19 Males and Females: An Exploratory Analysis of a Randomized, Double-Blinded, Placebo-Controlled Trial Early Antiandrogen Therapy with Proxalutamide

research Proxalutamide Improves Inflammatory, Immunologic, and Thrombogenic Markers in Mild-to-Moderate COVID-19 Males and Females: an Exploratory Analysis of a Randomized, Double-Blinded, Placebo-Controlled Trial Early Antiandrogen Therapy (EAT) with Proxalutamide (The EAT-Proxa Biochemical AndroCoV-Trial)

5 citations , July 2021 in “medRxiv (Cold Spring Harbor Laboratory)”

Proxalutamide improved blood markers related to inflammation, immune response, and clotting in COVID-19 patients, potentially reducing hospitalizations.

Proxalutamide Reduction of Mortality Rate in Hospitalized COVID-19 Patients Depends on Treatment Duration – An Exploratory Analysis of the Proxa-Rescue AndroCoV Trial

research Proxalutamide Reduction of Mortality Rate in Hospitalized COVID-19 Patients Depends on Treatment Duration – an Exploratory Analysis of the Proxa-Rescue AndroCoV Trial

5 citations , July 2021 in “bioRxiv (Cold Spring Harbor Laboratory)”

Completing a 14-day proxalutamide treatment significantly lowers death rates in hospitalized COVID-19 patients.

research Clinical course of alopecia after COVID-19

5 citations , May 2021 in “International Journal of Infectious Diseases”

A man experienced hair loss after getting COVID-19, which improved with treatment and might have been triggered by stress related to the illness.

5-Alpha-Reductase Inhibitors Reduce Remission Time of COVID-19: Results From a Randomized Double-Blind Placebo-Controlled Interventional Trial in 130 SARS-CoV-2 Positive Men

research 5-Alpha-Reductase Inhibitors Reduce Remission Time of COVID-19: Results From a Randomized Double Blind Placebo Controlled Interventional Trial in 130 SARS-CoV-2 Positive Men

5 citations , November 2020 in “medRxiv (Cold Spring Harbor Laboratory)”

5-Alpha-Reductase inhibitors shorten COVID-19 recovery time in men.

research Protective trend of anti-androgen therapy during the COVID-19 pandemic: A meta-analysis

4 citations , March 2022 in “Journal of Infection”

Anti-androgen therapy might help protect against COVID-19 infection and reduce death risk.

Androgenetic Alopecia in Women and Men Is Not Related to COVID-19 Infection Severity: A Prospective Cohort Study of Hospitalized COVID-19 Patients

research Androgenetic alopecia in women and men is not related to COVID‐19 infection severity: a prospective cohort study of hospitalized COVID‐19 patients

4 citations , May 2021 in “Journal of The European Academy of Dermatology and Venereology”

Hair loss doesn't affect COVID-19 severity.

research Effect of Epipharyngeal Abrasive Therapy on Long COVID with Chronic Epipharyngitis

2 citations , September 2022 in “Scholarly journal of otolaryngology”

Epipharyngeal Abrasive Therapy helps reduce symptoms in Long COVID patients with chronic epipharyngitis.

research Tofacitinib Treatment in Patients With Active COVID-19 Infection

2 citations , September 2021 in “Curēus”

Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.

research Reply to the Letter to the Editor “Androgen deprivation therapy may constitute a more effective prophylactic than therapeutic strategy in COVID-19 patients” by N. Bennani and I. M. Bennani-Baiti

2 citations , October 2020 in “Annals of Oncology”

Androgen deprivation therapy might help prevent severe COVID-19, but more research is needed.

research Cross-Sectional Perspective Study of Post-COVID Syndrome Characteristics in Benghazi, Libya

1 citations , January 2023 in “OALib”

Fatigue, loss of taste and smell, and cough are common long-term symptoms after COVID-19.

← Previous page